Compare BZH & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BZH | ARVN |
|---|---|---|
| Founded | 1985 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 672.0M | 781.0M |
| IPO Year | 1995 | 2018 |
| Metric | BZH | ARVN |
|---|---|---|
| Price | $19.04 | $10.10 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 20 |
| Target Price | ★ $32.00 | $15.35 |
| AVG Volume (30 Days) | 330.3K | ★ 670.7K |
| Earning Date | 04-30-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 58.84 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,087,739,000.00 | $262,600,000.00 |
| Revenue This Year | $4.36 | N/A |
| Revenue Next Year | $10.79 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.37 | $5.90 |
| 52 Week High | $28.33 | $14.22 |
| Indicator | BZH | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 28.82 | 31.91 |
| Support Level | $18.93 | $9.02 |
| Resistance Level | $23.75 | $10.18 |
| Average True Range (ATR) | 0.67 | 0.67 |
| MACD | -0.12 | -0.22 |
| Stochastic Oscillator | 13.47 | 4.18 |
Beazer Homes USA Inc is an construction company that focuses on residential construction. The company specializes in single-family housing and multi-unit building construction in states and metro markets. Beazer Homes builds homes and communities that target first-time, move-up, and luxury homebuyers with an average selling price of roughly $300,000. From a geographic perspective, home sales in the western and eastern United States have been the sources of revenue for the company. Its segments involve: West segment that includes Arizona, California, Nevada, and Texas; East segment that includes Delaware, Indiana, Maryland, Tennessee, and Virginia; and Southeast segment which includes Florida, Georgia, North Carolina, and South Carolina.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.